Integra LifeSciences (NASDAQ:IART) Coverage Initiated at Morgan Stanley

Investment analysts at Morgan Stanley initiated coverage on shares of Integra LifeSciences (NASDAQ:IART) in a note issued to investors on Monday,Briefing.com Automated Import reports. The brokerage set an “underweight” rating and a $20.00 price target on the life sciences company’s stock. Morgan Stanley’s price target suggests a potential downside of 18.63% from the stock’s current price.

Other equities research analysts have also issued research reports about the stock. Citigroup raised their price target on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday, November 5th. Bank of America cut their target price on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a research note on Monday, October 7th. Truist Financial lowered their price target on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research report on Monday, October 14th. Finally, BTIG Research raised Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, Integra LifeSciences presently has an average rating of “Hold” and a consensus price target of $23.00.

Integra LifeSciences Stock Up 0.2 %

IART opened at $24.58 on Monday. Integra LifeSciences has a 12 month low of $16.81 and a 12 month high of $45.42. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The business’s 50-day moving average price is $20.77 and its 200-day moving average price is $23.98. The company has a market cap of $1.90 billion, a P/E ratio of -273.11, a P/E/G ratio of 0.84 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.02. The business had revenue of $380.80 million for the quarter, compared to analysts’ expectations of $375.81 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business’s quarterly revenue was down .4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.76 EPS. On average, equities analysts expect that Integra LifeSciences will post 2.45 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Jane Street Group LLC grew its stake in Integra LifeSciences by 181.1% in the first quarter. Jane Street Group LLC now owns 124,887 shares of the life sciences company’s stock worth $4,427,000 after purchasing an additional 80,463 shares during the period. SG Americas Securities LLC grew its position in shares of Integra LifeSciences by 606.9% in the 2nd quarter. SG Americas Securities LLC now owns 67,471 shares of the life sciences company’s stock worth $1,966,000 after buying an additional 57,927 shares during the period. Versor Investments LP bought a new position in shares of Integra LifeSciences in the 3rd quarter worth about $612,000. Point72 Europe London LLP lifted its position in Integra LifeSciences by 13.8% during the 2nd quarter. Point72 Europe London LLP now owns 546,035 shares of the life sciences company’s stock valued at $15,911,000 after acquiring an additional 66,400 shares during the period. Finally, GSA Capital Partners LLP bought a new stake in Integra LifeSciences during the third quarter worth about $960,000. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.